Key Dates

Related Announcements

• July 26, 2022 - NCI Outstanding Investigator Award (R35 Clinical Trial Optional). See NOFO RFA-CA-22-045 

Issued by

National Cancer Institute (NCI)

Purpose

The purpose of this Notice of change is to add an eligible research grant mechanism in Section III Eligibility Information, Eligible Individuals, in RFA-CA-22-045, NCI Outstanding Investigator Award (R35 Clinical Trial Optional).

The following section of RFA-CA-22-045 is being changed to add an eligible research grant mechanism:

Section III. Eligibility Information. Eligible Individuals (Program Director/Principal Investigator).

Currently Reads:

2) The Institution-nominated PD/PI must have been a PD/PI or Project Leader of a research project (on a NIH-defined multi-project grant e.g., P01, P50, U54) excluding cores, on an eligible NCI research grant(s) continuously since:

• September 2017 for a November 2022 submission
• September 2018 for a November 2023 submission
• September 2019 for a November 2024 submission

Continuous funding is defined as receiving a Notice of Award as PD/PI for an eligible NCI-funded research grant in each Federal Fiscal Year beginning in FY 2017 (for Nov 2022 submission), FY 2018 (for Nov 2023 submission) or FY 2019 (for Nov 2024 submission) onward. Continuous funding does not include grants in a funded or unfunded extension. Eligible NCI research grant mechanisms are defined as R01, R15, R33, R35, R37, P01, P50, U01, U54, UM1, U19, U10, DP1, and DP2.

Changed to read (new text in italicized bold):

2) The Institution-nominated PD/PI must have been a PD/PI or Project Leader of a research project (on a NIH-defined multi-project grant e.g., P01, P50, U54) excluding cores, on an eligible NCI research grant(s) continuously since:

• September 2017 for a November 2022 submission
• September 2018 for a November 2023 submission
• September 2019 for a November 2024 submission

Continuous funding is defined as receiving a Notice of Award as PD/PI for an eligible NCI-funded research grant in each Federal Fiscal Year beginning in FY 2017 (for Nov 2022 submission), FY 2018 (for Nov 2023 submission) or FY 2019 (for Nov 2024 submission) onward. Continuous funding does not include grants in a funded or unfunded extension. Eligible NCI research grant mechanisms are defined as R01, R15, R33, R35, R37, P01, P50, U01, U54, UH3, UM1, U19, U10, DP1, and DP2.

All other aspects of RFA-CA-22-045 remain unchanged.

Inquiries

Please direct all inquiries to:

Scientific/Research Contact(s)

Christine Siemon
National Cancer Institute (NCI)
Telephone: 240-276-6266
Email:[email protected]

Peer Review Contact(s)

Shamala Srinivas, Ph.D.
National Cancer Institute (NCI)
Telephone: 240-276-6442
Email:[email protected]

Financial/Grants Management Contact(s)

Crystal Wolfrey
National Cancer Institute (NCI)
Telephone: 240-276-6277
Email:[email protected]